Evidence map›Paper›PMID 38746856›Full record

ArticleGlobal epidemiology2024

Evaluating algorithms for identifying incident Guillain-Barré Syndrome in Medicare fee-for-service claims.

Samantha R Eiffert, Brad Wright, Joshua Nardin, James F Howard, Rebecca Traub

Abstract read
In one paragraph

Article in Global epidemiology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Patient Outcomes Among Medicare Beneficiaries With Guillain-Barré Syndrome.Journal of the peripheral nervous system : JPNS · 2026
    Article
  6. Article
  7. Characterizing Guillain-Barré Risk Factors Among Traditional Medicare Beneficiaries.Inquiry : a journal of medical care organization, provision and financing
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Samantha R EiffertDivision of Pharmaceutical Outcomes and Policy, University of North Carolina School of Pharmacy, Chapel Hill, NC, USA.
Brad WrightHealth Services Policy and Management, Arnold School of Public Health, University of South Carolina, Columbia, SC, USA.
Joshua NardinDepartment of Neurology, University of North Carolina School of Medicine, Chapel Hill, NC, USA.
James F HowardDepartment of Neurology, University of North Carolina School of Medicine, Chapel Hill, NC, USA.
Rebecca TraubDepartment of Neurology, University of North Carolina School of Medicine, Chapel Hill, NC, USA.

Funding

North Carolina Translational and Clinical Sciences Institute (NC TraCS)UM1TR004406 · NCATS · UNIV OF NORTH CAROLINA CHAPEL HILL · PI NICHOLAS J SHAHEEN · 2023 to 2026
$37.5M
Using Medicare Claims to Advance Our Understanding of Guillain-Barre SyndromeR21NS119867 · NINDS · UNIV OF NORTH CAROLINA CHAPEL HILL · PI TRAUB, REBECCA · 2021 to 2021
$428k
NCATS NIH HHS UM1 TR004406NINDS NIH HHS R21 NS119867
6 · The paper itself

Abstract

Objective: Claims data can be leveraged to study rare diseases such as Guillain-Barré Syndrome (GBS), a neurological autoimmune condition. It is difficult to accurately measure and distinguish true cases of disease with claims without a validated algorithm. Our objective was to identify the best-performing algorithm for identifying incident GBS cases in Medicare fee-for-service claims data using chart reviews as the gold standard. Study design and setting: This was a multi-center, single institution cohort study from 2015 to 2019 that used Medicare-linked electronic health record (EHR) data. We identified 211 patients with a GBS diagnosis code in any position of an inpatient or outpatient claim in Medicare that also had a record of GBS in their electronic medical record. We reported the positive predictive value (PPV = number of true GBS cases/total number of GBS cases identified by the algorithm) for each algorithm tested. We also tested algorithms using several prevalence assumptions for false negative GBS cases and calculated a ranked sum for each algorithm's performance. Results: We found that 40 patients out of 211 had a true case of GBS. Algorithm 17, a GBS diagnosis in the primary position of an inpatient claim and a diagnostic procedure within 45 days of the inpatient admission date, had the highest PPV (PPV = 81.6%, 95% CI (69.3, 93.9). Across three prevalence assumptions, Algorithm 15, a GBS diagnosis in the primary position of an inpatient claim, was favored (PPV = 79.5%, 95% CI (67.6, 91.5). Conclusions: Our findings demonstrate that patients with incident GBS can be accurately identified in Medicare claims with a chart-validated algorithm. Using large-scale administrative data to study GBS offers significant advantages over case reports and patient repositories with self-reported data, and may be a potential strategy for the study of other rare diseases.

Indexed as

AlgorithmChart reviewGBSGuillain-Barré syndromeMedicareValidation

Identifiers

PMID38746856
PMCPMC11090889

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.